This study is to evaluate the efficacy of neoadjuvant long-term treatment with tislelizumab in combination with SOX in the treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma.
Willing to participate in this study, able to sign the informed consent form, and with compliance;
No gender restriction, aged ≥18 and ≤70 years (at the time of signing the informed consent form);
ECO score of 0-1;
Estimated survival ≥6 months;
Have had or simultaneously have other active malignant tumors within 5 years. Cured localized tumors, as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, and breast in situ, are eligible;
Patients who are preparing for or have previously undergone organ or bone marrow transplantation;
Have ≥2 grade myocardial ischem or myocardial infarction, arrhythmia (QTc ≥470ms), and ≥2 grade congestive heart failure (New York Heart AssociationNYHA] classification);
Human immunodeficiency virus (HIV) infection;
Single group
Tislelizumab + SOX
Drugtislelizumab combined with SOX
Pathologic complete response rate (pCR)
The R0 resection rate after radical operation
Major Pathological response (MPR) after radical operation
Event Free Survival Rate from baseline to 1 year
Overall Survival rate from baseline to 1 year
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
